Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Liposomes
Patent
1996-10-11
1999-01-12
Kishore, Gollamudi S.
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Liposomes
514824, 604 27, 604 28, A61K 9127, A61K 9133
Patent
active
058584005
ABSTRACT:
The present invention provides compositions for, a method of suppressing the rise in plasma concentrations of atherogenic lipoproteins after administration of an agent having small acceptors of cholesterol, other lipids or compounds. The method includes the step of co-administering an effective amount of a multiplicity of an agent having large liposomes that include phospholipids substantially free of sterol with the administration of the agent having the small acceptors. The atherogenic lipoproteins include LDL, VLDL, IDL, .beta.-VLDL, Lp(a), a lipoprotein containing apolipoprotein-B, oxidized lipoproteins, and modified lipoproteins. The agent having small acceptors consists essentially of small acceptors and in which the agent having large liposomes consists essentially of large liposomes. In a variant, co-administration of the agent having large liposomes is simultaneous with the administration of the agent having small acceptors. Optionally, co-administration of the agent having large liposomes is separated in time from the administration of the agent having small acceptors by an effective time period. An improved pharmaceutical composition for reducing the size of arterial lesions that enters the liver of a subject is also provided the improvement comprises an anti-oxidant and derivatives thereof. The invention also provides an improved mode of operation of liposomes utilizing the improvements described herein.
REFERENCES:
patent: 4532089 (1985-07-01), MacDonald
patent: 4812314 (1989-03-01), Barenholz et al.
patent: 5013556 (1991-05-01), Woodle
patent: 5015483 (1991-05-01), Haynes
patent: 5489611 (1996-02-01), Lee et al.
patent: 5556637 (1996-09-01), Hager et al.
patent: 5622715 (1997-04-01), Barenholz et al.
patent: 5741514 (1998-04-01), Barenholz et al.
Williams, et al., Intravenously Administered Lecithin Liposomes: A Synthetic Antiatherogenic Lipid Particle; Perspectives in Biology and Medicine; 27, 3; Spring 1984; pp. 417-431.
Daida et al., Prevention of Restenosis After Percutaneous Transluminal Coronary Angioplasty by Reducing Lipoprotein (a) Levels With Low-Density Lipoprotein Apheresis, Jun. 1, 1994, vol. 73, No. 15, pp. 1037-1040.
Desmarais et al., Elevated Serum Lipoprotein(a) is a Risk Factor for Clinical Recurrence After Coronary Balloon Angioplasty, Circulation, vol. 91, No. 5, Mar. 1, 1995, pp. 1403-1409.
Groop et al., Lipoprotein(a) In Type 1 Diabetic Patients with Renal Disease, Original Articles, May 11, 1994, pp. 961-967.
Kokoglu et al., Elevated Serum Lp(a) Levels In The Early and Advanced stages of Breast Cancer, Cancer Biochem, Biophys., 1994, vol. 14, pp. 133-136.
Kuriyama et al., Low Levels of Serum Apoliprotein A I and A II Senile Dementia, The Japanese Journal of Psychiatry and Neurology, vol. 48, No. 3, 1994, pp. 589-593.
Sachs, Bernard A., et al., In Vivo Effects of Inositol Phosphatide (Lipositol) In Serum Lipids and Atherosclerosis of Hyperlipemic Rabbits, J. Appl. Physiol., 15:983-986, 1960.
Takahashi et al., Increased Concentrations of Serum Lp(a) Lipoprotein in Patients With Primary Gout, Annals of The Rheumatic Diseases 1995, vol. 54, pp. 90-93.
Tenda et al., The Relationship Between Serum Lipoprotein(a) And Restenosis After Initial Elective Percutaneous Transluminal Coronary Angioplasty, Japanese Circulation Journal, vol. 57, Aug., 1993, pp. 789-795.
Williams et al., Uptake of Endogenous Cholesterol by a Synthetic Lipoprotein, Elsevier Science Publishers B.V. (Biomedical Division), 1986, pp. 183-194.
Yamamoto et al., Serum Lipoprotein (a) Levels Before and After Subtotal Thyroidectomy In Subjects With Hyperthyroidism, Metabolism, vol. 44, No. 1 (Jan.), 1995, pp. 4-7.
Williams in Liposome as drug carriers, Ed. by Gregoniado John Wiley & Sons Ltd. 1988 p. 93.
Williams Perspectives in Biology & Medicine 27, #3, p. 417, 1986.
Williams BBA 875, p. 183 (1986).
Kishore Gollamudi S.
Talaria Therapeutics, Inc.
LandOfFree
Method of suppressing a rise in LDL concentrations after adminis does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of suppressing a rise in LDL concentrations after adminis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of suppressing a rise in LDL concentrations after adminis will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1512315